
GenSight Biologics Updates Cash Position and Business as of June 30, 2024
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharmaceutical company specializing in innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, has announced its cash position as of June 30, 2024, and provided a comprehensive business…












